Duchenne Muscular Dystrophy: Start of the pivotal phase of Genethon's gene therapy trial
A new milestone has been reached in the clinical trial of gene therapy conducted by the Généthon laboratory for Duchenne muscular dystrophy.
AFM-Telethon
Welcome to AFM-Telethon's website
Latest news
International Crigler-Najjar Day: A Treatment in Trial
June 21 marks International Crigler-Najjar Syndrome Day. This rare genetic liver disease forces patients to live under intensive phototherapy. Thanks to a gene therapy developed by Généthon, the hope of a life without lamps is becoming a reality for some. But not all patients have access to it yet.
Cure Through Innovation 2025: AFM-Téléthon, Driving Force Behind a New Medicine
Discover Cure Through Innovation 2025, the reference brochure presenting at a glance the core missions, commitments, and achievements of AFM-Téléthon. An essential document to grasp the diversity of its actions and the emergence of an innovative medicine born from 65 years of fighting.
International FSHD Day: Where Does Research Stand?
On June 20, for International Facioscapulohumeral Muscular Dystrophy (FSHD) Day, AFM-Téléthon reaffirms its commitment to individuals living with the disease and provides an update on recent research progress.
Most requested content
Our fight to cure
Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services:
ou
Change my preferences60 years of fight against diseases
The French Muscular Dystrophy Association (AFM-Téléthon) is composed of patients and their families who are affected by genetic, rare and progressive diseases. Discover 60 years of fight.
Join the Telethon for french people abroad
You live abroad and want to be part of the great Telethon adventure? Join us!